Eyenovia, Inc. (EYEN)
Stock Price:
$2.63 USD
0.00 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT - Market open
After-hours: $2.66 +0.03 (1.14%) Jul 15, 4:00 PM
Key Info
| Market Cap |
52.01M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-20.68M |
| Shares Out |
19.78M |
| EPS (ttm) |
-1.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 15, 2020 |
| Last Price |
$2.63 |
| Previous Close |
$2.63 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
2.63 - 2.72 |
| Day's Volume |
0 |
| 52-Week Range |
1.11 - 5.06 |
More Stats
| Market Cap |
52.01M |
| Enterprise Value |
38.78M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.78M |
| Float |
12.42M |
| EPS (basic) |
-1.32 |
| EPS (diluted) |
-1.32 |
| FCF / Share |
-1.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
103,080 |
| Short Ratio |
1.14 |
| Short % of Float |
0.80% |
| Beta |
2.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.19 |
| Revenue |
n/a |
| Operating Income |
-20.83M |
| Net Income |
-20.68M |
| Free Cash Flow |
-19.16M |
| Net Cash |
13.23M |
| Net Cash / Share |
0.67 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-86.97% |
| ROE |
-166.84% |
| ROIC |
1,239.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(394.30% upside)
Low
6.00
Current: 2.63
High
19.00
Target: 13.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -21.31 | -17.26 | -5.13 | -3.53 | -4.27 |
| Net Income | -21.16 | -17.25 | -5.13 | -3.53 | -4.27 |
| Shares Outstanding | 14.35 | 9.48 | 2.34 | 2.27 | 2.27 |
| Earnings Per Share | -1.47 | -1.82 | -2.19 | -1.56 | -1.88 |
| Operating Cash Flow | -18.92 | -13.11 | -4.73 | -3.20 | -3.83 |
| Capital Expenditures | -0.17 | -0.03 | -0.01 | -0.04 | - |
| Free Cash Flow | -19.09 | -13.14 | -4.74 | -3.25 | -3.83 |
| Cash & Equivalents | 14.15 | 19.73 | 5.25 | 3.39 | 2.49 |
| Net Cash / Debt | 14.15 | 19.73 | 5.25 | 3.39 | 2.49 |
| Assets | 14.70 | 20.02 | 5.64 | 3.43 | 2.82 |
| Liabilities | 2.96 | 3.14 | 0.55 | 0.42 | 0.42 |
| Book Value | 11.74 | 16.88 | 5.09 | 3.01 | 2.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Eyenovia, Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
Sean Ianchulev |
Stock Information
| Ticker Symbol |
EYEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EYEN |
| IPO Date |
January 25, 2018 |
Description
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.